Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Truist raised the price target to $190 from $142. Goldman Sachs and Mizuho also updated ratings, with Goldman Sachs expecting momentum to continue in 2026. Mizuho raised the price target to $207, stating 2026 looks better for Biogen Inc.

Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company with a medicine portfolio that treats diseases like MS, SMA, Alzheimer’s, and ALS. The company markets various products for MS, SMA, Friedreich’s Ataxia, and other conditions. While BIIB is a potential investment, certain AI stocks may offer greater upside potential.

For more insights on potential stocks, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.” This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Here’s What Analysts Think About Biogen Inc. (BIIB)